{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:38:04Z","timestamp":1792636684263,"version":"4.5.0"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82471112"],"award-info":[{"award-number":["82471112"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ajo.2026.09.034","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:09:49Z","timestamp":1790723389000},"page":"733-751","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Teprotumumab for Thyroid Eye Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials and Real-World Studies"],"prefix":"10.1016","volume":"292","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3521-3629","authenticated-orcid":false,"given":"Aimin","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yedi","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahui","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jizhe","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2080-1414","authenticated-orcid":false,"given":"Yuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ajo.2026.09.034_bib0001","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s41574-024-01016-5","article-title":"Graves disease: latest understanding of pathogenesis and treatment options","volume":"20","author":"Lanzolla","year":"2024","journal-title":"Nat Rev Endocrinol"},{"issue":"7","key":"10.1016\/j.ajo.2026.09.034_bib0002","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/S2213-8587(25)00066-X","article-title":"Thyroid eye disease (Graves' orbitopathy): clinical presentation, epidemiology, pathogenesis, and management","volume":"13","author":"Wiersinga","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.ajo.2026.09.034_bib0003","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1001\/jamaophthalmol.2022.3225","article-title":"Utility assessment of moderate to severe thyroid eye disease health states","volume":"141","author":"Smith","year":"2023","journal-title":"JAMA Ophthalmol"},{"issue":"12","key":"10.1016\/j.ajo.2026.09.034_bib0004","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1089\/thy.2022.0251","article-title":"Management of thyroid eye disease: a consensus statement by the American Thyroid Association and the European Thyroid Association","volume":"32","author":"Burch","year":"2022","journal-title":"Thyroid"},{"issue":"3","key":"10.1016\/j.ajo.2026.09.034_bib0005","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1001\/archophthalmol.2011.29","article-title":"Rundle and his curve","volume":"129","author":"Bartley","year":"2011","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ajo.2026.09.034_bib0006","doi-asserted-by":"crossref","DOI":"10.1177\/2042018820958335","article-title":"Glucocorticoids in Graves' orbitopathy: mechanisms of action and clinical application","volume":"11","author":"L\u00e4ngericht","year":"2020","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.ajo.2026.09.034_bib0007","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1210\/jc.2012-2389","article-title":"Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy","volume":"97","author":"Bartalena","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.ajo.2026.09.034_bib0008","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1210\/endrev\/bnae018","article-title":"Teprotumumab for the treatment of thyroid eye disease","volume":"45","author":"Ugradar","year":"2024","journal-title":"Endocr Rev"},{"issue":"18","key":"10.1016\/j.ajo.2026.09.034_bib0009","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for thyroid-associated ophthalmopathy","volume":"376","author":"Smith","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ajo.2026.09.034_bib0010","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the treatment of active thyroid eye disease","volume":"382","author":"Douglas","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ajo.2026.09.034_bib0011","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1210\/clinem\/dgad637","article-title":"Efficacy and safety of teprotumumab in patients with thyroid eye disease of long duration and low disease activity","volume":"109","author":"Douglas","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.ajo.2026.09.034_bib0012","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1210\/clinem\/dgac627","article-title":"Teprotumumab-related hyperglycemia","volume":"108","author":"Amarikwa","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ajo.2026.09.034_bib0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajo.2022.02.015","article-title":"Hearing dysfunction after treatment with teprotumumab for thyroid eye disease","volume":"240","author":"Sears","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2026.09.034_bib0014","series-title":"JBI Manual for Evidence Synthesis","article-title":"Chapter 7: systematic reviews of etiology and risk","author":"Moola","year":"2020"},{"key":"10.1016\/j.ajo.2026.09.034_bib0015","article-title":"A randomised, double-masked, placebo-controlled trial evaluating the efficacy and safety of teprotumumab for active thyroid eye disease in Japanese patients","volume":"55","author":"Hiromatsu","year":"2025","journal-title":"Lancet Reg Health West Pac"},{"issue":"11","key":"10.1016\/j.ajo.2026.09.034_bib0016","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1001\/jamaophthalmol.2025.3350","article-title":"IGF-1R inhibitor IBI311 for the treatment of active thyroid eye disease in Chinese patients: the RESTORE-1 randomized clinical trial","volume":"143","author":"Zhang","year":"2025","journal-title":"JAMA Ophthalmol"},{"issue":"9","key":"10.1016\/j.ajo.2026.09.034_bib0017","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.ophtha.2026.04.022","article-title":"THRIVE: a phase 3, randomized, double-masked, placebo-controlled study of veligrotug for active thyroid eye disease","volume":"133","author":"Yen","year":"2026","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.ajo.2026.09.034_bib0019","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1097\/IOP.0000000000001959","article-title":"Rootman DB. Early experience with the clinical use of Teprotumumab in a heterogenous thyroid eye disease population","volume":"37","author":"Diniz","year":"2021","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"4","key":"10.1016\/j.ajo.2026.09.034_bib0020","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.ophtha.2021.10.017","article-title":"Teprotumumab efficacy, safety, and durability in longer-duration thyroid eye disease and re-treatment: OPTIC-X study","volume":"129","author":"Douglas","year":"2021","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ajo.2026.09.034_bib0021","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/IOP.0000000000002267","article-title":"Outcomes of patients with thyroid eye disease partially treated with teprotumumab","volume":"39","author":"Ho","year":"2022","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"3","key":"10.1016\/j.ajo.2026.09.034_bib0022","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/IOP.0000000000002563","article-title":"Teprotumumab and orbital decompression for the management of proptosis in patients with thyroid eye disease","volume":"40","author":"Hubschman","year":"2023","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"3","key":"10.1016\/j.ajo.2026.09.034_bib0023","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/IOP.0000000000002564","article-title":"Teprotumumab for the treatment of recalcitrant thyroid eye disease","volume":"40","author":"Men","year":"2023","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"1","key":"10.1016\/j.ajo.2026.09.034_bib0024","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/WNO.0000000000002001","article-title":"Objective diplopia outcomes for patients treated with teprotumumab for thyroid eye disease","volume":"44","author":"Mudalegundi","year":"2023","journal-title":"J Neuroophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2026.09.034_bib0025","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1080\/01676830.2021.1933081","article-title":"Teprotumumab for chronic thyroid eye disease","volume":"41","author":"Ozzello","year":"2021","journal-title":"Orbit"},{"issue":"9","key":"10.1016\/j.ajo.2026.09.034_bib0026","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1007\/s00417-024-06491-0","article-title":"Teprotumumab improves light sensitivity in patients with thyroid eye disease","volume":"262","author":"Parunakian","year":"2024","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2026.09.034_bib0027","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1136\/bjo-2024-325527","article-title":"Percent reduction in proptosis after teprotumumab treatment for thyroid eye disease","volume":"109","author":"Rosenblatt","year":"2025","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2026.09.034_bib0028","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1080\/01676830.2022.2122515","article-title":"Differential effects of teprotumumab treatment based on fat-to-muscle ratio in patients with thyroid eye disease","volume":"42","author":"Ting","year":"2022","journal-title":"Orbit"},{"issue":"10","key":"10.1016\/j.ajo.2026.09.034_bib0029","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1089\/thy.2023.0167","article-title":"Medical therapy in patients with moderate to severe, steroid-resistant, thyroid eye disease","volume":"33","author":"Toro-Tobon","year":"2023","journal-title":"Thyroid"},{"issue":"9","key":"10.1016\/j.ajo.2026.09.034_bib0030","doi-asserted-by":"crossref","DOI":"10.1097\/GOX.0000000000003809","article-title":"Facial and eyelid changes in thyroid eye disease are reversed by teprotumumab","volume":"9","author":"Ugradar","year":"2021","journal-title":"Plast Reconstr Surg Glob Open"},{"issue":"8","key":"10.1016\/j.ajo.2026.09.034_bib0031","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1038\/s41433-021-01593-z","article-title":"Teprotumumab for the treatment of chronic thyroid eye disease","volume":"36","author":"Ugradar","year":"2021","journal-title":"Eye (Lond)"},{"issue":"1","key":"10.1016\/j.ajo.2026.09.034_bib0032","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/IOP.0000000000002707","article-title":"Effects of teprotumumab on eyelid retraction in thyroid eye disease","volume":"41","author":"Al-Sharif","year":"2024","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"10","key":"10.1016\/j.ajo.2026.09.034_bib0033","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.eprac.2024.06.010","article-title":"Impact of teprotumumab on clinical practice in thyroid eye disease","volume":"30","author":"Rachmasari","year":"2024","journal-title":"Endocr Pract"},{"issue":"8","key":"10.1016\/j.ajo.2026.09.034_bib0034","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1007\/s00417-025-06855-0","article-title":"Time to improvement following teprotumumab treatment of thyroid eye disease: real world experience","volume":"263","author":"Lustig-Barzelay","year":"2025","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2026.09.034_bib0035","doi-asserted-by":"crossref","first-page":"325","DOI":"10.4103\/tjo.tjo_30_22","article-title":"Effect of teprotumumab on intraocular pressure in thyroid-associated ophthalmopathy","volume":"12","author":"Adetunji","year":"2022","journal-title":"Taiwan J Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2026.09.034_bib0036","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1097\/IOP.0000000000002611","article-title":"Teprotumumab for thyroid eye disease-related strabismus","volume":"40","author":"Dallalzadeh","year":"2024","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"4","key":"10.1016\/j.ajo.2026.09.034_bib0037","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.ophtha.2023.10.018","article-title":"Teprotumumab-related adverse events in thyroid eye disease: a multicenter study","volume":"131","author":"Shah","year":"2023","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ajo.2026.09.034_bib0038","doi-asserted-by":"crossref","DOI":"10.1097\/GOX.0000000000004287","article-title":"The effect of Teprotumumab on eyelid position in patients with thyroid eye disease","volume":"10","author":"Simmons","year":"2022","journal-title":"Plast Reconstr Surg Glob Open"},{"issue":"4","key":"10.1016\/j.ajo.2026.09.034_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaapos.2025.104275","article-title":"Strabismus patterns and surgical results in teprotumumab-treated thyroid eye disease: insights from a single-center study","volume":"29","author":"Walsh","year":"2025","journal-title":"J AAPOS"},{"issue":"4","key":"10.1016\/j.ajo.2026.09.034_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaapos.2024.103959","article-title":"The effect of teprotumumab infusion on ocular alignment in patients with symptomatic thyroid eye disease","volume":"28","author":"Zhang","year":"2024","journal-title":"J AAPOS"},{"issue":"3","key":"10.1016\/j.ajo.2026.09.034_bib0041","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/01676830.2025.2609906","article-title":"Teprotumumab associated menstrual changes","volume":"45","author":"Malik","year":"2026","journal-title":"Orbit"},{"issue":"4","key":"10.1016\/j.ajo.2026.09.034_bib0042","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/IOP.0000000000003126","article-title":"Longitudinal glycemic outcomes in patients with thyroid eye disease treated with teprotumumab","volume":"42","author":"Ha","year":"2026","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"1","key":"10.1016\/j.ajo.2026.09.034_bib0043","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s12020-026-04697-2","article-title":"Audiometric changes during teprotumumab therapy for thyroid eye disease: a prospective pilot study","volume":"91","author":"Van Swol","year":"2026","journal-title":"Endocrine"},{"key":"10.1016\/j.ajo.2026.09.034_bib0044","article-title":"Teprotumumab for thyroid eye disease: efficacy and impact on orbital decompression utilization","volume":"11","author":"Kumar","year":"2026","journal-title":"Laryngoscope Investig Otolaryngol"},{"key":"10.1016\/j.ajo.2026.09.034_bib0045","article-title":"Comparative outcomes of teprotumumab and tocilizumab in thyroid eye disease: the first retrospective study from the United Arab Emirates and Gulf Region of the Middle East","volume":"24","author":"Eatamadi","year":"2025","journal-title":"Semin Ophthalmol. Published online December"},{"issue":"5","key":"10.1016\/j.ajo.2026.09.034_bib0046","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1080\/01658107.2026.2673534","article-title":"Variability between changes in ocular alignment and Gorman diplopia score after teprotumumab in Thyroid eye disease","volume":"50","author":"Tamhankar","year":"2026","journal-title":"Neuroophthalmology"},{"key":"10.1016\/j.ajo.2026.09.034_bib0018","unstructured":"U.S. Food and Drug Administration. LUMVOA (veligrotug-vvze) Prescribing Information. Accessed September 11, 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/761530Orig1s000lbl.pdf"},{"issue":"5","key":"10.1016\/j.ajo.2026.09.034_bib0047","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s40265-020-01287-y","article-title":"Teprotumumab: first approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.ajo.2026.09.034_bib0049","doi-asserted-by":"crossref","first-page":"6348","DOI":"10.4049\/jimmunol.170.12.6348","article-title":"Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves' disease is mediated through the insulin-like growth factor I receptor pathway","volume":"170","author":"Pritchard","year":"2003","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.ajo.2026.09.034_bib0050","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1089\/thy.2010.0123","article-title":"Thyrotropin receptor-stimulating Graves' disease immunoglobulins induce hyaluronan synthesis by differentiated orbital fibroblasts from patients with Graves' ophthalmopathy not only via cyclic adenosine monophosphate signaling pathways","volume":"21","author":"van Zeijl","year":"2010","journal-title":"Thyroid"},{"issue":"2","key":"10.1016\/j.ajo.2026.09.034_bib0051","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1210\/jc.2012-1771","article-title":"Autoantibodies to the IGF1 receptor in Graves' orbitopathy","volume":"98","author":"Minich","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.ajo.2026.09.034_bib0052","doi-asserted-by":"crossref","first-page":"5076","DOI":"10.1210\/jc.2004-0716","article-title":"Immunoglobulins from patients with graves' disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor","volume":"89","author":"Smith","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.ajo.2026.09.034_bib0053","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2014-1580","article-title":"Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes","volume":"99","author":"Chen","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.ajo.2026.09.034_bib0054","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1001\/jamaophthalmol.2021.6284","article-title":"Proptosis and diplopia response with teprotumumab and placebo vs the recommended treatment regimen with intravenous methylprednisolone in moderate to severe thyroid eye disease: a meta-analysis and matching-adjusted indirect comparison","volume":"140","author":"Douglas","year":"2022","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2026.09.034_bib0055","doi-asserted-by":"crossref","first-page":"G43","DOI":"10.1530\/EJE-21-0479","article-title":"The 2021 European Group on Graves' orbitopathy (EUGOGO) Clinical Practice Guidelines for the Medical Management of Graves' orbitopathy","volume":"185","author":"Bartalena","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ajo.2026.09.034_bib0056","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1080204","article-title":"Update on the surgical management of Graves' orbitopathy","volume":"13","author":"Baeg","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"Suppl 1","key":"10.1016\/j.ajo.2026.09.034_bib0057","article-title":"THRIVE-2 phase 3 trial of veligrotug (VRDN-001) in chronic thyroid eye disease (TED): efficacy and safety at 15 weeks","volume":"9","author":"Jain","year":"2025","journal-title":"J Endocr Soc"},{"issue":"1","key":"10.1016\/j.ajo.2026.09.034_bib0058","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/WNO.0000000000001994","article-title":"Real-world experience with teprotumumab in patients with dysthyroid optic neuropathy","volume":"44","author":"Tamhankar","year":"2023","journal-title":"J Neuroophthalmol"},{"issue":"9","key":"10.1016\/j.ajo.2026.09.034_bib0059","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgad213","article-title":"The adverse effects profile of teprotumumab","volume":"108","author":"Stan","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.ajo.2026.09.034_bib0060","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.ophtha.2024.01.023","article-title":"Glycemic trends in patients with thyroid eye disease treated with teprotumumab in 3 clinical trials","volume":"131","author":"Smith","year":"2024","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2026.09.034_bib0061","article-title":"Teprotumumab in the management of thyroid eye disease: mechanistic insights and adverse reactions: a comprehensive review","volume":"16","author":"Xu","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"11","key":"10.1016\/j.ajo.2026.09.034_bib0062","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.ophtha.2021.04.024","article-title":"Teprotumumab: interpreting the clinical trials in the context of thyroid eye disease pathogenesis and current therapies","volume":"128","author":"Winn","year":"2021","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.ajo.2026.09.034_bib0063","doi-asserted-by":"crossref","DOI":"10.1097\/IOP.0000000000001943","article-title":"New-onset of inflammatory bowel disease in a patient treated with teprotumumab for thyroid associated ophthalmopathy","volume":"37","author":"Ashraf","year":"2021","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"10.1016\/j.ajo.2026.09.034_bib0064","article-title":"A case of ulcerative colitis associated with teprotumumab treatment for thyroid eye disease","volume":"22","author":"Safo","year":"2021","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"10","key":"10.1016\/j.ajo.2026.09.034_bib0065","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.ophtha.2025.05.012","article-title":"Long-term cardiovascular, renal, and safety outcomes of teprotumumab versus systemic glucocorticoids in thyroid eye disease: a target trial emulation","volume":"132","author":"Lo","year":"2025","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ajo.2026.09.034_bib0066","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ophtha.2024.07.018","article-title":"The rate of re-treatment in patients treated with teprotumumab: a multicenter study of 119 patients with 1 year of follow-up","volume":"132","author":"Ugradar","year":"2024","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ajo.2026.09.034_bib0067","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/WNO.0000000000002280","article-title":"Observational characterization of the retreatment course of patients with thyroid eye disease","volume":"45","author":"Chen","year":"2025","journal-title":"J Neuroophthalmol"},{"key":"10.1016\/j.ajo.2026.09.034_bib0068","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ajo.2023.12.001","article-title":"Reactivation after teprotumumab treatment for active thyroid eye disease","volume":"263","author":"Hwang","year":"2023","journal-title":"Am J Ophthalmol"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939426005490?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939426005490?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:42:09Z","timestamp":1792633329000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939426005490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":67,"alternative-id":["S0002939426005490"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2026.09.034","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Teprotumumab for Thyroid Eye Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials and Real-World Studies","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2026.09.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}